Search research articles
Contact Us
Filters
Showing results (11-20 of 14) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 14 results.
Scientific Reports
|
August 5, 2025
Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities`
Mashael Algethami, Ahmed Shoqafi, Ayat Lashen, et al.
Translational Oncology
|
February 17, 2026
Clinicopathological and functional evaluation of replication protein A in epithelial ovarian cancers: A target validation study
Mashael Algethami, Amera Sheha, Nehal Singhania, et al.
BMJ Open
|
November 22, 2023
Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres
Dean Fennell, Daniel Griffiths, Zina Eminton, et al.
Nature Communications
|
July 21, 2025
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial
Dean A Fennell, Kayleigh Hill, Min Zhang, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 14) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 14 results.
Scientific Reports
|
August 5, 2025
Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities`
Mashael Algethami, Ahmed Shoqafi, Ayat Lashen, et al.
Translational Oncology
|
February 17, 2026
Clinicopathological and functional evaluation of replication protein A in epithelial ovarian cancers: A target validation study
Mashael Algethami, Amera Sheha, Nehal Singhania, et al.
BMJ Open
|
November 22, 2023
Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres
Dean Fennell, Daniel Griffiths, Zina Eminton, et al.
Nature Communications
|
July 21, 2025
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial
Dean A Fennell, Kayleigh Hill, Min Zhang, et al.
Page
of 2